David V. Elkins
Net Worth

Last updated:

What is David V. Elkins net worth?

The estimated net worth of Mr. David V. Elkins is at least $29,482,566 as of 10 Mar 2022. He owns shares worth $3,369,250 as insider, has earned $6,673,316 from insider trading and has received compensation worth at least $19,440,000 in Bristol-Myers Squibb Company.

What is the salary of David V. Elkins?

Mr. David V. Elkins salary is $3,240,000 per year as Executive Vice President & Chief Financial Officer in Bristol-Myers Squibb Company.

How old is David V. Elkins?

Mr. David V. Elkins is 57 years old, born in 1968.

What stocks does David V. Elkins currently own?

As insider, Mr. David V. Elkins owns shares in one company:

Company Title Shares Price per share Total value
Bristol-Myers Squibb Company (BMY) Executive Vice President & Chief Financial Officer 69,699 $48.34 $3,369,250

What does Bristol-Myers Squibb Company do?

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

BMY logo
BMY
Bristol-Myers Squibb Company
$48.34

David V. Elkins insider trading

Bristol-Myers Squibb Company

Mr. David V. Elkins has made only one insider trade between 2019-2022, according to the Form 4 filled with the SEC.

As of 10 Mar 2022 he still owns at least 69,699 units of BMY stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock, $0.10 par value 8,042 N/A N/A
Option
Market Share Units 8,025 N/A N/A
Option
Common Stock, $0.10 par value 8,025 N/A N/A
Option
Market Share Units 8,042 N/A N/A
Option
Common Stock, $0.10 par value 24,577 N/A N/A
Option
Restricted Stock Units 24,577 N/A N/A
Option
Common Stock, $0.10 par value 47,401 N/A N/A
Option
Restricted Stock Units 47,401 N/A N/A
Option
Restricted Stock Units 8,792 N/A N/A
Option
Common Stock, $0.10 par value 8,792 N/A N/A
Sale
Common Stock, $0.10 par value 99,691 $66.94 $6,673,316
Option
Option (right to buy) 70,000 $48.49 $3,394,300
Option
Common Stock, $0.10 par value 70,000 $48.49 $3,394,300
Option
Common Stock, $0.10 par value 46,403 N/A N/A
Option
Restricted Stock Units 46,403 N/A N/A
Option
Restricted Stock Units 24,579 N/A N/A
Option
Common Stock, $0.10 par value 24,579 N/A N/A
Option
Common Stock, $0.10 par value 20,624 N/A N/A
Option
Restricted Stock Units 20,624 N/A N/A
Option
Common Stock, $0.10 par value 8,792 N/A N/A
Option
Restricted Stock Units 8,792 N/A N/A
Option
Restricted Stock Units 46,402 N/A N/A
Option
Common Stock, $0.10 par value 46,402 N/A N/A
Option
Restricted Stock Units 24,579 N/A N/A
Option
Common Stock, $0.10 par value 24,579 N/A N/A
Option
Restricted Stock Units 12,373 N/A N/A
Option
Common Stock, $0.10 par value 12,373 N/A N/A

Bristol-Myers Squibb Company key executives

Bristol-Myers Squibb Company executives and other stock owners filed with the SEC: